New diabetes drug candidate enters first human tests

NCT ID NCT07570992

Recruiting now Disease control Sponsor: Novo Nordisk A/S Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial is testing a new experimental medicine called NNC1679-0001 for type 2 diabetes. Researchers want to see if it is safe and how well the body tolerates it. The study includes both healthy volunteers and people with type 2 diabetes, who will receive either a single dose of the drug or a placebo injection. The results will help decide if further testing is warranted.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: NNC1679-0001
What this could lead to: If successful, this could lead to a new treatment option for type 2 diabetes that helps control blood sugar.
What could go wrong: This is a very early phase 1 trial with only 58 participants, so safety and effectiveness are not yet proven. Many experimental drugs fail at this stage.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIABETES MELLITUS, TYPE 2 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DIABETES MELLITUS, TYPE 2 HEALTHY VOLUNTEERS

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

Medical University of Graz
RECRUITING

Graz, 8010, Austria

More trials for these conditions

Other studies related to the condition(s) this trial covers.